Cleared Traditional

MEASLESVIRUS FLOURE. CONJUGATED ANTISERU (K770687) - FDA 510(k) Clearance

Class I Immunology device.

K770687 · Microbiological Assoc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1977
Decision
62d
Days
Class 1
Risk

K770687 is an FDA 510(k) clearance for the MEASLESVIRUS FLOURE. CONJUGATED ANTISERU. Classified as Antiserum, Fluorescent, Rubeola (product code GRE), Class I - General Controls.

Submitted by Microbiological Assoc. (Mchenry, US). The FDA issued a Cleared decision on June 14, 1977 after a review of 62 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.3520 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Microbiological Assoc. devices

Submission Details

510(k) Number K770687 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 13, 1977
Decision Date June 14, 1977
Days to Decision 62 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
42d faster than avg
Panel avg: 104d · This submission: 62d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GRE Antiserum, Fluorescent, Rubeola
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.3520
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.